UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 34, 2025

XERIS BIOPHARMA HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-40880

87-1082097

(State or other jurisdiction of
incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

1375 West Fulton Street, Suite 1300

Chicago, Illinois 60607

(Address of principal executive offices, including zip code)

(844) 445-5704

(Registrant's telephone number, including area code)

(Not ~~applicable)~~Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001 per share

XERS

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ¨☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 75.0107 Submission ~~Regulation~~of FDMatters ~~Disclosure~~to a Vote of Security Holders.

On June 4, 2025, Xeris Biopharma Holdings, Inc. (the “Company”) ~~will~~held ~~host~~ its ~~first Analyst and Investor Day on June 3,~~ 2025, inAnnual ~~New~~Meeting ~~York~~of ~~City.~~Stockholders ~~A slide presentation to be used by the Company's senior management in discussions with investors~~ (the “~~Presentation~~Annual Meeting”) ~~is attached as Exhibit 99~~.1 toAs ~~this~~of ~~Current~~April ~~Report~~14, on2025, ~~Form~~the ~~8-K~~record ~~and~~date ~~incorporated~~for ~~into~~the ~~this~~Annual ~~Item~~Meeting, ~~7.01~~there bywere ~~reference.~~156,384,578 Ashares ~~copy~~ of the ~~Presentation~~Company’s ~~will~~common ~~also~~stock beoutstanding ~~accessible~~and onentitled ~~the~~to ~~Company's~~vote ~~website~~ at ~~www.xerispharma.com under~~ the ~~“Investors”~~Annual ~~tab.~~Meeting, ~~A copy~~ of ~~the~~which ~~press~~111,098,912 ~~release~~shares ~~announcing~~were ~~the~~represented ~~Analyst~~by ~~and~~proxy, ~~Investor~~constituting ~~Day~~a isquorum ~~attached~~on asall ~~Exhibit~~matters 99voted upon.2 toThe ~~this~~final ~~Current~~voting ~~Report~~results onof ~~Form~~the ~~8-K~~Annual ~~and~~Meeting ~~incorporated~~are ~~into~~as ~~this~~follows: ~~Item 7.01 by reference.~~

~~The~~Proposal ~~information~~One: Election ~~in this Item 7.01, including Exhibit 99.1 and Exhibit 99.2, is being furnished and shall not be deemed to be “filed” for purposes~~ of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. In addition, the contents of the Company's website are not incorporated by reference into this Current Report on Form 8-K and you should not consider information provided on the Company's website to be a part of this Current Report on Form 8-K.Directors

~~Item~~As ~~9.01 Financial~~described ~~Statements~~in the Company’s Definitive Proxy Statement on Schedule 14A, filed on April 23, 2025 (“Proxy Statement”), the Company’s Board nominated three individuals to serve as Class I directors until the 2028 Annual Meeting of Stockholders, or until his or her successor has been duly elected and ~~Exhibits~~qualified, or until his or her earlier death, resignation, or removal. Each nominee was elected by a plurality vote in accordance with the Company’s Bylaws, as follows:

(d) Exhibits


Class I Director Nominee	For	Withhold	Broker Non-Votes
BJ Bormann	57,050,196	21,676,213	32,372,503
James Brady	76,465,887	2,260,522	32,372,503
Garheng Kong	75,938,627	2,787,782	32,372,503

Exhibit Number						Description
99.1						Investor Presentation
99.2						Press release, dated June 3, 2025, issued by the Company
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm

Stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025:


For	Against	Abstain	Broker Non-Votes
110,053,757	744,492	300,663	—

Proposal Three: Advisory Vote to Approve Named Executive Officer Compensation

The Company’s stockholders approved, on a non-binding advisory basis, to approve the compensation of the Company’s Named Executive Officers as disclosed in the Company’s Proxy Statement pursuant to the compensation disclosure rules of the Securities and Exchange Commission (the “Say-on-Pay Vote”). The Company’s stockholders voted as follows to approve such executive compensation pursuant to the Say-on-Pay Vote:


For	Against	Abstain	Broker Non-Votes
72,202,176	5,633,615	890,618	32,372,503

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 3, 2025

Xeris Biopharma Holdings, Inc.

Date: June 4, 2025

Xeris Biopharma Holdings, Inc.

By:

/s/ Steven M. Pieper

Name: Steven M. Pieper

Title: Chief Financial Officer

Filing Compare · Xeris Biopharma Holdings, Inc.